Brokers Issue Forecasts for ClearPoint Neuro, Inc.’s Q3 2024 Earnings (NASDAQ:CLPT)

ClearPoint Neuro, Inc. (NASDAQ:CLPT) – Investment analysts at B. Riley decreased their Q3 2024 earnings per share (EPS) estimates for ClearPoint Neuro in a report released on Thursday, August 8th. B. Riley analyst K. Bauser now anticipates that the company will post earnings per share of ($0.19) for the quarter, down from their prior forecast of ($0.18). B. Riley currently has a “Buy” rating and a $10.00 target price on the stock. The consensus estimate for ClearPoint Neuro’s current full-year earnings is ($0.66) per share.

ClearPoint Neuro Trading Up 1.3 %

CLPT stock opened at $9.91 on Monday. The firm has a 50 day moving average of $6.56 and a 200-day moving average of $6.46. The firm has a market capitalization of $271.73 million, a P/E ratio of -11.80 and a beta of 1.07. ClearPoint Neuro has a 12 month low of $4.05 and a 12 month high of $10.03.

ClearPoint Neuro (NASDAQ:CLPT) last issued its earnings results on Wednesday, August 7th. The company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.19) by $0.03. ClearPoint Neuro had a negative return on equity of 76.92% and a negative net margin of 78.84%. The business had revenue of $7.86 million during the quarter, compared to the consensus estimate of $7.50 million. During the same quarter last year, the company earned ($0.29) EPS.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. XTX Topco Ltd increased its holdings in shares of ClearPoint Neuro by 11.6% in the second quarter. XTX Topco Ltd now owns 13,010 shares of the company’s stock worth $70,000 after purchasing an additional 1,353 shares during the period. Price T Rowe Associates Inc. MD grew its position in ClearPoint Neuro by 7.9% during the first quarter. Price T Rowe Associates Inc. MD now owns 24,867 shares of the company’s stock worth $170,000 after buying an additional 1,813 shares in the last quarter. Rinkey Investments purchased a new position in ClearPoint Neuro during the second quarter worth about $307,000. Russell Investments Group Ltd. increased its stake in ClearPoint Neuro by 23,048.0% in the 1st quarter. Russell Investments Group Ltd. now owns 46,296 shares of the company’s stock worth $315,000 after acquiring an additional 46,096 shares during the last quarter. Finally, Legato Capital Management LLC raised its holdings in shares of ClearPoint Neuro by 21.6% in the 2nd quarter. Legato Capital Management LLC now owns 158,968 shares of the company’s stock valued at $857,000 after acquiring an additional 28,227 shares in the last quarter. 30.08% of the stock is owned by institutional investors.

About ClearPoint Neuro

ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.